NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries

Condition:   Corneal Persistent Epithelial Defect Interventions:   Drug: NEXAGON High Dose Concentration;   Drug: NEXAGON Low Dose Concentration;   Drug: NEXAGON Vehicle Sponsors:   OcuNexus Therapeutics, Inc.;   Eyevance Pharmaceuticals Not yet recruiting

Source: ClinicalTrials.gov - September 9, 2019 Category: Research Source Type: clinical trials